| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]()
CAS号:140-79-4
|
英文名称:N,N'-DINITROSOPIPERAZINE
分子式
C4H8N4O2
分子量
144
EINECS号
205-434-6
MDL
MFCD00014615
Smiles
InChIKey
乙二醇化学百科
基本信息
物化性质
安全信息
生产及用途
N,N'-Dinitrosopiperazine (1,4-Dinitrosopiperazine; DNP) 是一种致癌物 (carcinogen),特异性针对鼻咽癌,可促进鼻咽癌的转移。N,N'-Dinitrosopiperazine 通过蛋白磷酸化调节多种信号通路,包括 LYRIC,在丝氨酸 568 位。 N,N'-Dinitrosopiperazine (0.5-100 μM; 48 hours) has no inhibitory effects on the labeled 6-10B cells, and LDH activity is not significantly altered by DNP treatment in the 0.5-8 μM concentration range. However, it is cytotoxic from the concentration 10 μM.N,N'-Dinitrosopiperazine (2-8 μM; 24 hours) induces 6-10B cell invasion and motility in a dose-dependent manner. At 6 μM, when compares to the control group, DNP increases cell invasion at 421.7% and cell motility is increased by 328.2%.N,N'-Dinitrosopiperazine (6 μM; 24 hours) increases the expression of phospho-LYRIC s568 and LYRIC expression in CNE1 cells.
Cell Viability Assay
Western Blot Analysis
N,N'-Dinitrosopiperazine (injected into the tail veins; 40 mg/kg; 30 days) inhibits cell motility and invasion, and facilitates NPC metastasis in vivo. From a IHC result, Phospho-LYRIC expression is higher in the metastatic tumors of DNP-treated mice than in those of the untreated control mice.
上下游产品
产品供应商
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
本网站展示的所有产品仅用于工业制造、技术研发、科学研究,所有产品非药品不可食用,依据国家相关法规及平台管理要求,购买相关危险物品应取得有效的资质、资格条件。 参考《应急管理部等多部门关于加强互联网销售危险化学品安全管理的通知 (应急〔2022〕119号)》 和《互联网危险物品信息发布管理规定》 Copyright © 2021-2025 chemhome123版权所有 |冀ICP备2024096099号- 1|冀公安备13042302000143号|互联网增值电信业务经营许可证:冀B2-20250121 |药品、 医疗器械互联网信息服务备案凭证备案号:(冀)-非经营性-2025-0099 |